Sensei biotherapeutics announces collaboration with washington university, st. louis to support development of sns-101, a conditionally active vista-blocking antibody

- planned studies aimed at further elucidating the mechanism of sns-101's anti-tumor activity - - planned studies aimed at further elucidating the mechanism of sns-101's anti-tumor activity -

SNSE Ratings Summary

SNSE Quant Ranking